241 related articles for article (PubMed ID: 2743333)
1. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Chabot MC; Wykle RL; Modest EJ; Daniel LW
Cancer Res; 1989 Aug; 49(16):4441-5. PubMed ID: 2743333
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species.
Wagner BA; Buettner GR; Oberley LW; Burns CP
Cancer Res; 1998 Jul; 58(13):2809-16. PubMed ID: 9661895
[TBL] [Abstract][Full Text] [Related]
3. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues.
Powis G; Seewald MJ; Gratas C; Melder D; Riebow J; Modest EJ
Cancer Res; 1992 May; 52(10):2835-40. PubMed ID: 1316230
[TBL] [Abstract][Full Text] [Related]
5. The relationship between cellular ether glycerophospholipid content and sensitivity of cancer cells to 1-O-octadecyl-2-O-methyl-glycerophosphocholine.
Zhou X; Lu X; Arthur G
Anticancer Res; 1992; 12(5):1659-62. PubMed ID: 1444233
[TBL] [Abstract][Full Text] [Related]
6. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L).
Mollinedo F; Fernández-Luna JL; Gajate C; Martín-Martín B; Benito A; Martínez-Dalmau R; Modolell M
Cancer Res; 1997 Apr; 57(7):1320-8. PubMed ID: 9102220
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells.
Hoffman DR; Hoffman LH; Snyder F
Cancer Res; 1986 Nov; 46(11):5803-9. PubMed ID: 3756924
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine).
Marino-Albernas JR; Bittman R; Peters A; Mayhew E
J Med Chem; 1996 Aug; 39(17):3241-7. PubMed ID: 8765506
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
Seewald MJ; Olsen RA; Sehgal I; Melder DC; Modest EJ; Powis G
Cancer Res; 1990 Aug; 50(15):4458-63. PubMed ID: 2369723
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of leukemia cell lines to cytotoxic alkyl-lysophospholipids in relation to O-alkyl cleavage enzyme activities.
Unger C; Eibl H; Kim DJ; Fleer EA; Kötting J; Bartsch HH; Nagel GA; Pfizenmaier K
J Natl Cancer Inst; 1987 Feb; 78(2):219-22. PubMed ID: 3468284
[TBL] [Abstract][Full Text] [Related]
11. Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440.
Petersen ES; Kelley EE; Modest EJ; Burns CP
Cancer Res; 1992 Nov; 52(22):6263-9. PubMed ID: 1423272
[TBL] [Abstract][Full Text] [Related]
12. Different mechanisms of inhibition by alkyl-lysophospholipid and phorbol ester of granulocyte-macrophage colony-stimulating factor binding to human leukemic cell lines.
Shoji M; Fukuhara T; Winton EF; Berdel WE; Vogler WR
Exp Hematol; 1994 Jan; 22(1):13-8. PubMed ID: 8282054
[TBL] [Abstract][Full Text] [Related]
13. Quaternary ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines.
Civoli F; Daniel LW
Cancer Chemother Pharmacol; 1998; 42(4):319-26. PubMed ID: 9744778
[TBL] [Abstract][Full Text] [Related]
14. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine.
Ahmad I; Filep JJ; Franklin JC; Janoff AS; Masters GR; Pattassery J; Peters A; Schupsky JJ; Zha Y; Mayhew E
Cancer Res; 1997 May; 57(10):1915-21. PubMed ID: 9157985
[TBL] [Abstract][Full Text] [Related]
15. Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Small GW; Strum JC; Daniel LW
Lipids; 1997 Jul; 32(7):715-23. PubMed ID: 9252959
[TBL] [Abstract][Full Text] [Related]
16. The differential susceptibility of A427 and A549 cell lines to the growth-inhibitory effects of ET-18-OCH3 does not correlate with the relative effects of the alkyl-lysophospholipid on the incorporation of fatty acids into cellular phospholipids.
Lu X; Arthur G
Cancer Res; 1992 May; 52(10):2813-7. PubMed ID: 1581895
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues.
Berggren MI; Gallegos A; Dressler LA; Modest EJ; Powis G
Cancer Res; 1993 Sep; 53(18):4297-302. PubMed ID: 8395981
[TBL] [Abstract][Full Text] [Related]
18. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
Magistrelli A; Villa P; Benfenati E; Modest EJ; Salmona M; Tacconi MT
Drug Metab Dispos; 1995 Jan; 23(1):113-8. PubMed ID: 7720513
[TBL] [Abstract][Full Text] [Related]
19. The antitumor ether lipid 1-Q-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1.
Samadder P; Richards C; Bittman R; Bhullar RP; Arthur G
Anticancer Res; 2003; 23(3B):2291-5. PubMed ID: 12894505
[TBL] [Abstract][Full Text] [Related]
20. The degradation of platelet-activating factor and related lipids: susceptibility to phospholipases C and D.
Wilcox RW; Wykle RL; Schmitt JD; Daniel LW
Lipids; 1987 Nov; 22(11):800-7. PubMed ID: 3444369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
